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• Colorectal cancer (CRC) is the third leading cause of 
cancer-related deaths in the US.1
• KRAS mutation is present in 45% of all CRC cases1, but 
no targeted therapies have been approved.
• Vertical MAPK inhibition therapy consisting of MEK and 
CDK4/6 inhibitors is currently in a Phase II clinical trial.
• Despite the initial response to targeted therapies, most 
cancers develop resistance.
• The aims of this project include:
1. Modeling resistance of KRAS-mutated CRC to 
vertical MAPK inhibitor combination therapies in 
vitro.
2. Investigating the mechanisms driving resistance.  
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BACKGROUND & OBJECTIVES
Figure 1. Overview of the KRAS pathway. 
METHODS
2. Gateway Cloning
1. Developing Resistance
Figure 2. KRASmut colorectal cancer cells were drugged with 
vertical MAPK inhibition combination therapy to developed 
resistance. Two distinct resistant phenotypes identified: colonies
and persister cells. RNA-seq analysis was conducted on both 
sensitive and resistant cells to identify differentially expressed 
genes.
Figure 3. Fifteen (15) entry clones corresponding to the 15 
differentially expressed genes were designed and introduced into 
a doxycycline-inducible destination vector. The plasmids were 
then transduced into KRASmut CRC cells using lentiviruses.
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Figure 4. RNA-seq identified eleven (11) genes that are 
upregulated in persisters, compared to parental cells and resistant 
colonies. The genes are implicated in the MAPK pathway.
Figure 5. RNA-seq identified four (4) genes that are differentially 
expressed across the different cell types. The genes are 
implicated in the MAPK pathway.
We determined that:
1. KRASmut colorectal cancer cells acquire resistance to 
vertical MAPK inhibition combination therapy upon 
long-term exposure.
2. Resistant cells display two distinct phenotypes: isolated 
persisters and resistant colonies.
3. Eleven (11) genes are upregulated in persisters and 
four (4) are differentially expressed across all cell 
types. 
We successfully designed plasmids that will enable us to 
overexpress each of the 15 genes in KRASmut colorectal 
cancer cells.
Future directions:
1. Overexpress the genes in parental cells prior to 
drugging to determine whether they confer resistance.
2. Overexpress the genes in resistant colonies to 
determine whether they produce the persister
phenotype.
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Gene JUN BMP2 EGR1 TRIB1 ETV1 ETV5
Length (bp) 992 1190 1631 1183 1080, 353 1532
Gene MAFF FOS FOSB FOSL1 ETV4 CCND1
Length (bp) 494 1142 1016 815 1249, 205 887
Figure 6. Gel electrophoresis confirming the formation of the 
correct Gateway cloning plasmids for 12 target genes. The 
plasmids had been digested with the BsrGI restriction enzyme. 
